Synonyms: AF-2838 | AF2838
Compound class:
Synthetic organic
Comment: Bindarit is a compound with anti-inflammatory activity. In vitro, that is primarily associated with an inhibition of MCP-1 (CCL2) production and subsequent reduction in monocyte recruitment and differentiation. It has been shown to directly interact with fatty acid binding protein 4 (FABP4) and this is proposed to underlie its mechanism of action [1]. In this mechanism bindarit modulates the phosphorylation state of p38α and AKT2 and selectively increases FABP4 expression, all in a PPARγ-dependent manner, and these effects are associated with a decrease in MCP-1 production.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Immunopharmacology Comments |
Bindarit is an orally bioactive anti-inflammatory compound, that inhibits the production of certain C-C motif chemokines, such as MCP-1 (CCL2). It thereby interferes with monocyte recruitment and differentiation. Safety of bindarit in humans has been demonstrated in clinical trials. Elevated levels of CCL2 and proinflammatory monocyte infiltration are associated with persistent periodontal inflammation, such as observed in diabetes-associated periodontitis (DP). Bindarit-induced Inhibition of CCL2 has been proposed as a therapeutic option for DP [2]. |